Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients.

ABSTRACT:

SUBMITTER: Maffioli M 

PROVIDER: S-EPMC6855128 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature